Gut microbiome in cirrhotic hepatitis C virus patients with and without hepatocellular carcinoma

Khaled Mohieldeen1, Soraya Abdel Fatah Hamoda1, Saad Ahmed2, Abdurrahman Najeeb1, Walid Ismail Ellakany1
1Tropical Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2Medical Microbiology and Immunology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Tóm tắt

Abstract Background Chronic hepatitis C is the most common cause of chronic liver disease and hepatocellular carcinoma in Egypt. A pathogenic link with gut microbial dysbiosis has been described in different diseases. The aim of the study is to elucidate changes in gut microbiome in cirrhotic HCV Egyptian patients with and without HCC. Results The study included 50 cirrhotic HCV patients; 25 with and 25 without HCC and 25 healthy controls with matched age and sex. Stool specimens were taken from all participants. Quantitative SYBR Green real-time PCR technique targeting 16S rRNA was done for the identification and quantitation of selected bacterial phylum, genera, and/or species. Both HCC and cirrhosis groups showed decrease in Firmicutes, F/B ratio, A. mucinophilia, and F. prausnitzii compared to the control group. However, the HCC group only showed statistically significant increase in Bacteroides and Lactobacilli, and decrease of Prevotella relative abundance and P/B ratio compared to both cirrhosis and control groups. As regard the relation between the gut microbiome and stages of HCC, BCLC stage D showed significantly the lowest relative abundance of Ruminococcus. Conclusion Patients with HCV-related cirrhosis and HCC exhibit microbial dysbiosis; altered microbial relative abundance and diversity with HCC patients showing higher proinflammatory bacteria compared to cirrhotics.

Từ khóa


Tài liệu tham khảo

Organization WH (2017) Global hepatitis report 2017. Geneva: World Health Organization

Centers for Disease Control and Prevention (CDC) (2012) Progress toward prevention and control of hepatitis C virus infection--Egypt, 2001-2012. MMWR Morb Mortal Wkly Rep 61(29):545–9.

Waked I, Esmat G, Elsharkawy A, El-Serafy M, Abdel-Razek W, Ghalab R et al (2020) Screening and treatment program to eliminate hepatitis C in Egypt. N Engl J Med 382(12):1166–1174. https://doi.org/10.1056/NEJMsr1912628

Cresci GA, Bawden E (2015) Gut microbiome: what we do and don’t know. Nutr Clin Pract 30(6):734–746. https://doi.org/10.1177/0884533615609899

Dzutsev A, Badger JH, Perez-Chanona E, Roy S, Salcedo R, Smith CK, Trinchieri G (2017) Microbes and cancer. Annu Rev Immunol 35(1):199–228. https://doi.org/10.1146/annurev-immunol-051116-052133

Shahanavaj K, Gil-Bazo I, Castiglia M, Bronte G, Passiglia F, Carreca AP, del Pozo JL, Russo A, Peeters M, Rolfo C (2015) Cancer and the microbiome: potential applications as new tumor biomarker. Expert Rev Anticancer Ther 15(3):317–330. https://doi.org/10.1586/14737140.2015.992785

Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338(6103):120–123. https://doi.org/10.1126/science.1224820

Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M et al (2015) Cancer and the gut microbiota: an unexpected link. Sci Transl Med 7(271):271ps1-ps1

Yu L-X, Schwabe RF (2017) The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 14(9):527–539. https://doi.org/10.1038/nrgastro.2017.72

Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA (2019) The microbiome, cancer, and cancer therapy. Nat Med 25(3):377–388. https://doi.org/10.1038/s41591-019-0377-7

Morkūnas E, Skiecevičienė J, Kupčinskas J (2020) The impact of modulating the gastrointestinal microbiota in cancer patients. Best Pract Res Clin Gastroenterol 101700:101700. https://doi.org/10.1016/j.bpg.2020.101700

Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G (2017) Anticancer effects of the microbiome and its products. Nat Rev Microbiol 15(8):465–478. https://doi.org/10.1038/nrmicro.2017.44

Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, Routy B, Jacquelot N, Apetoh L, Becharef S, Rusakiewicz S, Langella P, Sokol H, Kroemer G, Enot D, Roux A, Eggermont A, Tartour E, Johannes L, Woerther PL, Chachaty E, Soria JC, Golden E, Formenti S, Plebanski M, Madondo M, Rosenstiel P, Raoult D, Cattoir V, Boneca IG, Chamaillard M, Zitvogel L (2016) Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity. 45(4):931–943. https://doi.org/10.1016/j.immuni.2016.09.009

Gensollen T, Iyer SS, Kasper DL, Blumberg RS (2016) How colonization by microbiota in early life shapes the immune system. Science. 352(6285):539–544. https://doi.org/10.1126/science.aad9378

Guarner F, Malagelada J-R (2003) Gut flora in health and disease. Lancet 361(9356):512–519. https://doi.org/10.1016/S0140-6736(03)12489-0

Natividad JMM, Verdu EF (2013) Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol Res 69(1):42–51. https://doi.org/10.1016/j.phrs.2012.10.007

den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud D-J, Bakker BM (2013) The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 54(9):2325–2340. https://doi.org/10.1194/jlr.R036012

Bäumler AJ, Sperandio V (2016) Interactions between the microbiota and pathogenic bacteria in the gut. Nature. 535(7610):85–93. https://doi.org/10.1038/nature18849

Acharya C, Sahingur SE, Bajaj JS (2017) Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight 2(19):e94416. https://doi.org/10.1172/jci.insight.94416

Bhat M, Arendt BM, Bhat V, Renner EL, Humar A, Allard JP (2016) Implication of the intestinal microbiome in complications of cirrhosis. World J Hepatol 8(27):1128–1136. https://doi.org/10.4254/wjh.v8.i27.1128

Tsochatzis EA, Bosch J, Burroughs AK (2014) Liver cirrhosis. Lancet 383(9930):1749–1761

Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y (2018) Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis 67(6):869–877. https://doi.org/10.1093/cid/ciy205

Darnaud M, Faivre J, Moniaux N (2013) Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol 58(2):385–387. https://doi.org/10.1016/j.jhep.2012.08.019

Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649. https://doi.org/10.1002/bjs.1800600817

Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391(10127):1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2

Nadkarni MA, Martin FE, Jacques NA, Hunter N (2002) Determination of bacterial load by real-time PCR using a broad-range (universal) probe and primers set. Microbiology 148(Pt 1):257–266

Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S (2007) Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol 73(23):7767–7770. https://doi.org/10.1128/AEM.01477-07

Bergström A, Licht TR, Wilcks A, Andersen JB, Schmidt LR, Grønlund HA, Vigsnaes LK, Michaelsen KF, Bahl MI (2012) Introducing GUt low-density array (GULDA): a validated approach for qPCR-based intestinal microbial community analysis. FEMS Microbiol Lett 337(1):38–47. https://doi.org/10.1111/1574-6968.12004

Rinttilä T, Kassinen A, Malinen E, Krogius L, Palva A (2004) Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 97(6):1166–1177. https://doi.org/10.1111/j.1365-2672.2004.02409.x

Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P (2009) Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr 101(4):541–550. https://doi.org/10.1017/S0007114508019880

Tomova A, Husarova V, Lakatosova S, Bakos J, Vlkova B, Babinska K, Ostatnikova D (2015) Gastrointestinal microbiota in children with autism in Slovakia. Physiol Behav 138:179–187. https://doi.org/10.1016/j.physbeh.2014.10.033

Shannon CE (1948) A mathematical theory of communication. Bell Sys Techn J 27(3):379–423. https://doi.org/10.1002/j.1538-7305.1948.tb01338.x

Bray JR, Curtis JT (1957) An ordination of the upland forest communities of Southern Wisconsin. Ecol Monogr 27(4):325–349. https://doi.org/10.2307/1942268

Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A et al (2016) Hepatocellular carcinoma: a review. J Hepatocellular Carcinoma 3:41–53. https://doi.org/10.2147/JHC.S61146

Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D et al (2011) Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54(2):562–572

Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM (2014) Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 60(5):940–947. https://doi.org/10.1016/j.jhep.2013.12.019

Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, Xu S, Zhang H, Cui G, Chen X, Sun R, Wen H, Lerut JP, Kan Q, Li L, Zheng S (2019) Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 68(6):1014–1023. https://doi.org/10.1136/gutjnl-2017-315084

Zheng R, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F (2020) Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. Cancer Med 9(12):4232–4250. https://doi.org/10.1002/cam4.3045

Gérard P (2013) Metabolism of cholesterol and bile acids by the gut microbiota. Pathogens. 3(1):14–24. https://doi.org/10.3390/pathogens3010014

Piñero F, Vazquez M, Baré P, Rohr C, Mendizabal M, Sciara M, Alonso C, Fay F, Silva M (2019) A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma. Ann Hepatol 18(3):480–487. https://doi.org/10.1016/j.aohep.2018.10.003

Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L, Del Chierico F et al (2019) Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 69(1):107–120

Aly AM, Adel A, El-Gendy AO, Essam TM, Aziz RK (2016) Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog 8(1):42. https://doi.org/10.1186/s13099-016-0124-2

Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R, Brodesser S et al (2020) Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC. Clin Transl Gastroenterol 11(3):e00131-e

Wu Y-N, Zhang L, Chen T, Li X, He L-H, Liu G-X (2020) Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation. World J Gastroenterol 26(36):5420–5436. https://doi.org/10.3748/wjg.v26.i36.5420

Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR et al (2011) Enterotypes of the human gut microbiome. Nature. 473(7346):174–180. https://doi.org/10.1038/nature09944

Thorburn Alison N, Macia L, Mackay CR (2014) Diet, metabolites, and “Western-Lifestyle” inflammatory diseases. Immunity. 40(6):833–842. https://doi.org/10.1016/j.immuni.2014.05.014

Chen W, Wang S, Wu Y, Shen X, Guo Z, Li Q, Xing D (2020) Immunogenic cell death: a link between gut microbiota and anticancer effects. Microb Pathog 141:103983. https://doi.org/10.1016/j.micpath.2020.103983

Yamamoto K, Kuzuya T, Honda T, Ito T, Ishizu Y, Nakamura M et al (2020) Relationship between adverse events and microbiomes in advanced hepatocellular carcinoma patients treated with sorafenib. Anticancer Res 40(2):665–676. https://doi.org/10.21873/anticanres.13996